RECIPIENT PRETRANSPLANT INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY IN NONMYELOABLATIVE HCT

Mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), inhibits inosine monophosphate dehydrogenase (IMPDH) activity. IMPDH is the rate-limiting enzyme involved in de novo synthesis of guanosine nucleotides and catalyzes the oxidation of inosine 5’-monophosphate (IMP) to xanthosine 5’-monophosphate (XMP). We developed a highly sensitive liquid chromatography–mass spectrometry method to quantitate XMP concentrations in peripheral blood mononuclear cells (PMNC) isolated from the recipient pretransplant and used this method to determine IMPDH activity in 86 nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) patients. The incubation procedure and analytical method yielded acceptable within-sample and within-individual variability. Considerable between-individual variability was observed (12.2-fold). Low recipient pretransplant IMPDH activity was associated with increased day +28 donor T-cell chimerism, more acute graft-versus-host disease (GVHD), lower neutrophil nadirs, and more cytomegalovirus reactivation, but not with chronic GVHD, relapse, non-relapse mortality, or overall mortality. We conclude that quantitation of the recipient’s pretransplant IMPDH activity in PMNC lysate could provide a useful biomarker to evaluate a recipient’s sensitivity to MMF, but confirmatory studies are needed. Further trials should be conducted to confirm our findings and to optimize postgrafting immunosuppression in nonmyeloablative HCT recipients.

[1]  P. Hari,et al.  Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. , 2013, Biology of Blood and Marrow Transplantation.

[2]  Kremena V. Star,et al.  Histologic Features in Colon Biopsies Can Discriminate Mycophenolate From GVHD-induced Colitis , 2013, The American journal of surgical pathology.

[3]  B. Sandmaier,et al.  Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  B. Sandmaier,et al.  Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil , 2013, Journal of clinical pharmacology.

[5]  Bernhard O. Palsson,et al.  The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models , 2013, BMC Systems Biology.

[6]  B. Sandmaier,et al.  A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration‐Time Curve in Hematopoietic Cell Transplantation Recipients , 2012, Journal of clinical pharmacology.

[7]  M. Vij,et al.  Mycophenolate mofetil-induced colitis with graft versus host disease-like features in a liver transplant recipient. , 2012, Indian journal of pathology & microbiology.

[8]  Hong Wang,et al.  [Efficacy and safety of low-dose cyclophosphamide plus corticosteroids for type I/II myasthenia gravis]. , 2012, Zhonghua yi xue za zhi.

[9]  S. Mineishi Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go. , 2011, JAMA.

[10]  B. Wall,et al.  Patterns of injury in mycophenolate mofetil-related colitis. , 2010, Transplantation proceedings.

[11]  F. Berthoux,et al.  Differential effect of cyclosporine and mycophenolic acid on the human regulatory T cells and TH-17 cells balance. , 2009, Transplantation proceedings.

[12]  Jason Y. Park,et al.  Mycophenolic Acid (Cellcept and Myofortic) Induced Injury of the Upper GI Tract , 2009, The American journal of surgical pathology.

[13]  G. Gerken,et al.  Mycophenolic Acid Impedes the Antigen Presenting and Lymph Node Homing Capacities of Human Blood Myeloid Dendritic Cells , 2009, Transplantation.

[14]  B. Sandmaier,et al.  A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients , 2009, Clinical Cancer Research.

[15]  K. Budde,et al.  Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells , 2009, Therapeutic drug monitoring.

[16]  D. Jain,et al.  Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil , 2009, Modern Pathology.

[17]  P. Martin Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation , 2009 .

[18]  Brian R. Phillips,et al.  A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients , 2009, Cancer Chemotherapy and Pharmacology.

[19]  R. Lechler,et al.  Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. , 2008, The Journal of clinical investigation.

[20]  J. Parfitt,et al.  Mycophenolate Mofetil-related Gastrointestinal Mucosal Injury: Variable Injury Patterns, Including Graft-versus-Host Disease-like Changes , 2008, The American journal of surgical pathology.

[21]  A. Kiani,et al.  Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation , 2008, Bone Marrow Transplantation.

[22]  M. Maris,et al.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.

[23]  N. Le,et al.  Regulating regulatory T cells , 2007, Bone Marrow Transplantation.

[24]  F. Baron,et al.  Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning , 2006, Leukemia.

[25]  S. Bergan,et al.  Determination of Inosine Monophosphate Dehydrogenase Activity in Human CD4+ Cells Isolated from Whole Blood During Mycophenolic Acid Therapy , 2006, Therapeutic drug monitoring.

[26]  H. Deeg,et al.  Optimization of allogeneic transplant conditioning: not the time for dogma , 2006, Leukemia.

[27]  M. Maris,et al.  Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  H. Deeg,et al.  A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  R. Storb,et al.  Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. , 2005, Blood reviews.

[30]  K. Budde,et al.  Pre‐Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  J. Radich,et al.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2004, Blood.

[32]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[33]  M. Raab,et al.  Influence of mycophenolic acid on inosine 5'-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[34]  K. Budde,et al.  Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. , 2001, Clinical biochemistry.

[35]  R. Ponec,et al.  Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. , 1999, Gastrointestinal endoscopy.

[36]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[37]  B. Mitchell,et al.  Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. , 1995, Biochemical pharmacology.

[38]  R. Lo,et al.  Etiology and outcome of diarrhea after marrow transplantation: a prospective study. , 1994, Gastroenterology.

[39]  Y. Natsumeda,et al.  Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). , 1994, Life sciences.

[40]  Y. Natsumeda,et al.  Characterization of human type I and type II IMP dehydrogenases. , 1993, The Journal of biological chemistry.

[41]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[42]  G Weber,et al.  Two distinct cDNAs for human IMP dehydrogenase. , 1990, The Journal of biological chemistry.

[43]  F. Collart,et al.  Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs. , 1988, The Journal of biological chemistry.

[44]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.